HOME > TOP STORIES
TOP STORIES
-
REGULATORY Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
-
BUSINESS Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
-
REGULATORY Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
-
BUSINESS Metal Found in Voltaren Product Again: Novartis
April 17, 2014
-
ORGANIZATION Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
-
BUSINESS FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
-
BUSINESS Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
-
ACADEMIA Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
-
BUSINESS 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
-
BUSINESS Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
-
BUSINESS Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
-
BUSINESS India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
-
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
-
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
-
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
-
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
ページ
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
